A new fluorescently labeled bisphosphonate for theranostics in tumor bone metastasis

Talanta. 2021 Dec 1:235:122796. doi: 10.1016/j.talanta.2021.122796. Epub 2021 Aug 11.

Abstract

Bone metastasis of malignant solid tumors has become one of the most serious complications, especially in breast cancer, which was particularly challenging for early detection and treatment in clinical practice. In this work, we reported a new fluorescently labeled bisphosphonate for bone metastasis detection of breast cancer. The designed probes were based on Rhodamine B and bisphosphonate as recognition group, which can specifically target hydroxyapatite (HA) existed in bone tissue. After the osteoclasts were adsorbed on the bone surface, the surrounding microenvironment was acidified, causing the HA to locally dissolve. The probe bound to the HA was then released, and realized the fluorescence turn on under acidic conditions. In vitro experiments showed that G0 was more excellent than G2 owing to shorter connecting arm. Subsequently, we proved that G0 could combine with HA rapidly and exhibit excellent response in solid state. More importantly, we established a model of bone metastasis with MDA-MB-231 cells which was similar to the clinical cases and evaluated the theranostics value of G0 prospectively, which provide the potential application prospect in clinical.

Keywords: Bisphosphonate; Bone metastasis; Fluorescence imaging; Hydroxyapatite; pH-sensitivity.

MeSH terms

  • Bone Neoplasms* / drug therapy
  • Bone and Bones
  • Breast Neoplasms* / drug therapy
  • Diphosphonates
  • Female
  • Humans
  • Osteoclasts
  • Precision Medicine
  • Tumor Microenvironment

Substances

  • Diphosphonates